HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
6fjb8VMEHwzqWd5y